Literature DB >> 11549316

A high-resolution 6.0-megabase transcript map of the type 2 diabetes susceptibility region on human chromosome 20.

S C Fossey1, J C Mychaleckyj, J K Pendleton, J R Snyder, J T Bensen, S Hirakawa, S S Rich, B I Freedman, D W Bowden.   

Abstract

Recent linkage studies and association analyses indicate the presence of at least one type 2 diabetes susceptibility gene in human chromosome region 20q12-q13.1. We have constructed a high-resolution 6.0-megabase (Mb) transcript map of this interval using two parallel, complementary strategies to construct the map. We assembled a series of bacterial artificial chromosome (BAC) contigs from 56 overlapping BAC clones, using STS/marker screening of 42 genes, 43 ESTs, 38 STSs, 22 polymorphic, and 3 BAC end sequence markers. We performed map assembly with GraphMap, a software program that uses a greedy path searching algorithm, supplemented with local heuristics. We anchored the resulting BAC contigs and oriented them within a yeast artificial chromosome (YAC) scaffold by observing the retention patterns of shared markers in a panel of 21 YAC clones. Concurrently, we assembled a sequence-based map from genomic sequence data released by the Human Genome Project, using a seed-and-walk approach. The map currently provides near-continuous coverage between SGC32867 and WI-17676 ( approximately 6.0 Mb). EST database searches and genomic sequence alignments of ESTs, mRNAs, and UniGene clusters enabled the annotation of the sequence interval with experimentally confirmed and putative transcripts. We have begun to systematically evaluate candidate genes and novel ESTs within the transcript map framework. So far, however, we have found no statistically significant evidence of functional allelic variants associated with type 2 diabetes. The combination of the BAC transcript map, YAC-to-BAC scaffold, and reference Human Genome Project sequence provides a powerful integrated resource for future genomic analysis of this region.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549316     DOI: 10.1006/geno.2001.6584

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  6 in total

1.  Identification of P-Rex1 as a novel Rac1-guanine nucleotide exchange factor (GEF) that promotes actin remodeling and GLUT4 protein trafficking in adipocytes.

Authors:  Demis Balamatsias; Anne M Kong; Joanne E Waters; Absorn Sriratana; Rajendra Gurung; Charles G Bailey; John E J Rasko; Tony Tiganis; S Lance Macaulay; Christina A Mitchell
Journal:  J Biol Chem       Date:  2011-10-15       Impact factor: 5.157

2.  Systems genetics of metabolism: the use of the BXD murine reference panel for multiscalar integration of traits.

Authors:  Pénélope A Andreux; Evan G Williams; Hana Koutnikova; Riekelt H Houtkooper; Marie-France Champy; Hugues Henry; Kristina Schoonjans; Robert W Williams; Johan Auwerx
Journal:  Cell       Date:  2012-08-30       Impact factor: 41.582

3.  Insulin modulates the secretion of proteins from mature 3T3-L1 adipocytes: a role for transcriptional regulation of processing.

Authors:  P Wang; J Keijer; A Bunschoten; F Bouwman; J Renes; E Mariman
Journal:  Diabetologia       Date:  2006-08-04       Impact factor: 10.122

Review 4.  The role of HNF4A variants in the risk of type 2 diabetes.

Authors:  Karen L Mohlke; Michael Boehnke
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

5.  Heterogeneity in gene loci associated with type 2 diabetes on human chromosome 20q13.1.

Authors:  J L Bento; N D Palmer; M Zhong; B Roh; J P Lewis; M R Wing; H Pandya; B I Freedman; C D Langefeld; S S Rich; D W Bowden; J C Mychaleckyj
Journal:  Genomics       Date:  2008-08-09       Impact factor: 5.736

6.  Genetic analysis of the GLUT10 glucose transporter (SLC2A10) polymorphisms in Caucasian American type 2 diabetes.

Authors:  Jennifer L Bento; Donald W Bowden; Josyf C Mychaleckyj; Shohei Hirakawa; Stephen S Rich; Barry I Freedman; Fernando Segade
Journal:  BMC Med Genet       Date:  2005-12-07       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.